Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Accelerated BEP chemotherapy for intermediate- and poor-risk metastatic germ cell tumour
ISRCTN18505589Phase 2Completed
- Sponsor
- Cambridge University Hospitals NHS Foundation Trust
- Start
- Aug 2004
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Phase 2, open-label, single-arm trial of bleomycin, etoposide, cisplatin and granulocyte colony-stimulating factor in germ cell tumor (GCT), sponsored by Cambridge University Hospitals NHS Foundation Trust. Primary endpoints: Feasibility and Toxicity. Started Aug 2004; status: completed.
02
Drugs
bleomycinetoposidecisplatingranulocyte colony-stimulating factor
03
Conditions
germ cell tumor (GCT)
Beyond the preview
Go deeper on ISRCTN18505589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN18505589.